Figure 2 | Scientific Reports

Figure 2

From: Drug Signature-based Finding of Additional Clinical Use of LC28-0126 for Neutrophilic Bronchial Asthma

Figure 2

Effects of LC28-0126 on differential cell counts and protein levels of inflammatory cytokines in OVALPS-OVA mice.

All parameters were measured at 48 hrs after the last challenge in saline-sensitized and challenged mice administered with drug vehicle (SV), OVALPS-OVA mice with drug vehicle (OLV), OVALPS-OVA mice 3 mg/kg of LC28-0126 (OLNE3), or OVALPS-OVA mice with 30 mg/kg of LC28-0126 (OLNE30) (a) Differential cell counts in BAL fluids in LC28-0126-treated OVALPS-OVA mice. Bars represent mean ± SEM from 7 mice per group. (b) Expression of inflammatory mediators in LC28-0126-treated OVALPS-OVA mice. Bars represent mean ± SEM from 5 mice per group. #p < 0.05 vs. SV or Control; *p < 0.05 vs. OLV.

Back to article page